Today's Rundown Featured Story | | | Tuesday, April 2, 2019 Sangamo saw its stock on the up this morning after the company posted updates to a series of its trials using a new form of gene editing and cell therapies. |
|
|
Top Stories Monday, April 1, 2019 Merck is set to cut 20 staffers from its Research Laboratories unit as it prepares to enter its new digs in South San Francisco. Monday, April 1, 2019 Bayer has shared preliminary clinical data on the second TRK inhibitor it licensed from Loxo Oncology. The phase 1 trial linked the drug to a 45% response rate in a subpopulation of solid tumor patients resistant or intolerant to a prior TRK inhibitor. Monday, April 1, 2019 Deloitte discusses how biotech companies are exploring alternative strategies to fund growth including IPOs, collaborative arrangements, and share-based payment arrangements. Tuesday, April 2, 2019 Fusion Pharmaceuticals reeled in $105 million in new capital to push a clinical-stage program and build a pipeline of new treatments and combination therapies. Monday, April 1, 2019 After a number of pacts and buyouts over the past few years, Charles River Labs is cutting staff at one of its California sites. Tuesday, April 2, 2019 The FDA has rebuffed Evoke Pharma’s nasal spray Gimoti, a version of the decades-old oral drug metoclopramide, on worries the spray device isn't delivering "reproducible" dosing, a company executive said Tuesday. The agency's ruling isn't a complete surprise, but Evoke shares slid, anyway. Resources Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
